Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study

Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study

Abstract Introduction Idarucizumab, a monoclonal antibody fragment that rapidly reverses the anticoagulant effects of dabigatran, was approved in Japan in September 2016, at which time an all-case, postmarketing surveillance (PMS) study was initiated to collect data on idarucizumab in Japanese patie...

Full description

Bibliographic Details
Main Authors: Masahiro Yasaka, Hiroyuki Yokota, Michiyasu Suzuki, Hidesaku Asakura, Teiichi Yamane, Yukako Ogi, Takaaki Kimoto, Daisuke Nakayama
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-10-01
Series:Cardiology and Therapy
Subjects:
Anticoagulation
Dabigatran
Emergency reversal
Idarucizumab
Japanese postmarketing surveillance
Online Access:https://doi.org/10.1007/s40119-023-00333-6

Internet

https://doi.org/10.1007/s40119-023-00333-6

Similar Items